Target intelligence / Profile preview

PDGFR, TGF-βR, and VEGFR

Target: PDGFR, TGF-βR, and VEGFR

Overview

While all three are prominent, druggable receptor tyrosine kinases (and/or serine/threonine kinases) and are often targeted together by multi-kinase inhibitors in oncology and fibrosis, they are separated proteins, not a single "target" by strict molecular definition. The combination is only correct when referring to inhibitor spectrum, not a unique "canonical" biological entity. Each should be addressed separately as above for standardization.

Beyond the preview

Go deeper on PDGFR, TGF-βR, and VEGFR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDGFR, TGF-βR, and VEGFR.

Explore the full profile